Milatuzumab

• CAT Number: I041575
• CAS Number: 899796-83-9
• Purity: ≥95%

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].
Milatuzumaba (5 μg/mL; 8-48 h) enhances cell death in MCL cell lines and primary patient tumor cells[1].
Milatuzumaba (5 μg/mL; 0.5-2 h) mediates the cytotoxicity partially depending on generation of ROS and loss of mitochondrial transmembrane potential in Jeko, Mino, and SP-53 cells[1].
Milatuzumaba (5 μg/mL; 4 h) inhibits NF-κB pathway and induces cell apoptosis with independent of caspase cleavage, Bcl-2 family member dysregulation, or induction of autophagy[1].
Milatuzumaba (15 mg/kg/day; i.p.; once every 3 days) significantly increases the survival rate of female SCID mice bearing Jeko cells. And Milatuzumaba has a synergistic effect with Rituximab (HY-P9913) in mouse model[1].

Reference

[1]. Alinari L, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41.
 [Content Brief]